I am an individual investor who has been actively involved in the healthcare and biotechnology space for over 15 years. I hold a PhD in the biomedical sciences and have worked in both large pharmaceutical and small biotech companies. I make investments based on the fundamentals of a company and if I believe they have a superior technology or products compared to the competition. I'm an investor who believes patience pays off.
My name is Dr Kanak Kanti De, MBBS, MD, PhD, retired medical practitioner, cancer survivor, healthcare sector investor, over 30 years' experience in the sector both in India and the United States. I write/have written on Motley Fool, SeekingAlpha, Benzinga, and on Forbes. I am consistently ranked high on TipRanks, although I don't like their ranking system. My portfolio has consistently beat the various indices for years. Email me to discuss my articles, or for just an adda (Bengali for informal chat) email@example.com.
PRIMARY OBJECTIVE: ... Income Replacement!
Escape velocity is the speed that an object needs to be traveling to break free of the planet's gravitational pull and leave it without further propulsion.
This portfolio is looking for the point where the income being generated can allow the holder of this portfolio to escape the gravitational pull of the market and economic forces of worrying about share prices.
The objective is to generate enough income from assets that the only selling of shares will become an option, not a necessity to survive. Therefore, with enough income being generated, it minimizes the fear of meaningful market corrections as dividends are based on the number of shares owned, not the share price.
My goal is to bring exposure to business development companies (BDCs) that finance small to medium sized businesses, typically overlooked by banks. BDCs are an instrument for investors to earn healthy dividends by avoiding double taxation at the corporate level and allowing income to flow directly to each shareholder. Please see website link below for more information.
A researcher into gene silencing as a technology for improving the lives of those suffering from incurable diseases. Benitec Biopharma is my primary investment in this technology as ddRNAi offers one-time treatments for a broad range of these diseases.
Thomas H. Kee Jr., is President and CEO of Stock Traders Daily. The Stock of the Week Strategy offered by Stock Traders Daily may be the best performing strategy on the market since December, 2007 (before the credit crisis), and "The Investment Rate" is arguably the best measure of the underlying economy available anywhere (it is a macroeconomic work). Our reports and analysis are currently offered by Reuters Research to their institutional clients. Economic analysis and forecasting is provided to a variety of institutional and retail clientele through Stock Traders Daily's corporate website. Mr. Kee had worked with Smith Barney, AG Edwards, and Morgan Stanley before founding Stock Traders Daily in January 2000. Stock Traders daily thrived during the Internet Debacle. (http://stocktradersdaily.com/)
I am an early career scientific researcher who has taken a strong interest in investing, both for achieving my personal financial goals as well as serving as an alternative conduit where critical and logical thinking are appreciated and rewarded. I write articles to share ideas, refine my own thinking and invite discussion from the astute readership of Seeking Alpha.
For a better Seeking Alpha experience on your phone, please consider viewing the website on your browser (request desktop site for full functionality) instead of through the Seeking Alpha app.
Within the academic field, I have a career total of 87 articles and 5 book chapters, 2,600 total citations and an h-index of 31 (metrics from Google Scholar).
Steven Bavaria writes about finance, economics and politics, drawing on his forty-five years experience in international banking, credit, investment, human resources/training, journalism and public service. Now retired from his "day job" on Wall Street, Bavaria lives mostly off his investments. His focus is largely on income-oriented stocks, bonds and mutual funds, as well as closed-end funds, ETFs and other IRA-suitable investments. His book "Too Greedy for Adam Smith: CEO Pay and the Demise of Capitalism" was just published and is available on Amazon and at independent retailers.
Bavaria began his career at the Bank of Boston, where he handled international credit workouts that included managing a fleet of ships, chasing a Vatican-owned bank in Switzerland, and leading the turnaround of troubled branches in Australia and Panama. He also ran the bank's human resources department, which is where he saw personally the beginnings of many of today's executive compensation excesses.
More recently he worked at Standard & Poor's, where he introduced ratings to the leveraged loan market. In between Bank of Boston and S&P he was Assoc. Commissioner of the Massachusetts Dept. of Mental Health, worked briefly for Citibank, and was a reporter for IDD Magazine. He also did a short stint at a smaller rating agency where he had to leave in a hurry after writing an article called "From Banker to Bookmaker" that was deemed a bit too candid in describing the conflicted role of major commercial and investment banks.
Bavaria graduated from Georgetown University and New England School of Law.
Charles (Chuck) C. Carnevale is the creator of F.A.S.T. Graphs™. Chuck is also co-founder of an investment management firm. He has been working in the securities industry since 1970: he has been a partner with a private NYSE member firm, the President of a NASD firm, Vice President and Regional Marketing Director for a major AMEX listed company, and an Associate Vice President and Investment Consulting Services Coordinator for a major NYSE member firm. Prior to forming his own investment firm, he was a partner in a 30-year-old established registered investment advisory in Tampa, Florida. Chuck holds a Bachelor of Science in Economics and Finance from the University of Tampa. Chuck is a sought-after public speaker who is very passionate about spreading the critical message of prudence in money management. Chuck is a Veteran of the Vietnam War and was awarded both the Bronze Star and the Vietnam Honor Medal.
Over 30 years of investing in individual stocks. Extensive business experience with small to mid-size companies, including as CEO. Many hundreds of blog posts on financial and economic matters since 2008. Focus on value with catalysts for upside price action. Background as a physician and pharmaceutical inventor and entrepreneur, however focus now is global and involves almost all economic categories.
I'm the author of five published books, an investor and a cancer survivor. I got my start thirty-two years ago doing research for a UCLA economics professor who wrote a stock-picking newsletter. I have been involved in information technology, dental and medical research (former clinical editor with Dentistry Today magazine) and software design. Right now, I'm finishing my sixth book, and writing articles on Seeking Alpha for others who (like me) enjoy doing extensive investment research and profiting from it.